Chief Business Officer · Syndax Pharmaceuticals Inc (SNDX)

Anjali Ganguli

FY2021 is the first fiscal year CompBrief holds for Anjali Ganguli as a named executive officer of Syndax Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,069,653

Salary $308,580Stock awards $193,600

4th of 4 named executive officers at Syndax Pharmaceuticals by FY2021 total.

4 named officers on file for Syndax Pharmaceuticals, FY2021

Anjali Ganguli’s pay file — $29

  • 1 fiscal year of pay, line by line
  • SNDX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syndax Pharmaceuticals’s whole pay program stands against its peers

  • Syndax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SNDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 29, 2022 (DEF 14A).

Free

Get Anjali Ganguli’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anjali Ganguli compensation by year

Syndax Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Syndax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$308,580
Bonus$0
Stock awards$193,600
Option awards$1,425,473
Non-equity incentive$134,000
Pension and deferred compensation$0
All other$8,000
Total$2,069,653

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed March 29, 2022, accession 0001564590-22-012198, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0001564590-22-012198. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$218,900—
Option37,000—$21.36
Option45,833—$19.36
Option15,625—$9.47
Option11,646—$6.38
Option2,444—$6.38
Option379—$9.63

Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Syndax Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Briggs MorrisonChief Executive Officer$3,904,316
Michael MetzgerChief Executive Officer$3,333,905
Daphne KarydasFormer Chief Financial Officer$2,278,520
Anjali Ganguli · this pageChief Business Officer$2,069,653

The full Syndax Pharmaceuticals compensation record

free company brief

This page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Syndax Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anjali Ganguli's compensation dossier · One-time report. No refunds.